Immuron (IMRN) Income from Non-Controlling Interests (2016 - 2023)
Immuron's quarterly Income from Non-Controlling Interests came in at $2.1 million in Q4 2023, up 4.52% year-on-year from $2.0 million in Q4 2022, and up 4.52% quarter-over-quarter from $2.0 million in Q4 2022.
Immuron has reported Income from Non-Controlling Interests for 8 years, with the latest figure at $2.1 million in Q4 2023.
- For the quarter ending Q4 2023, Income from Non-Controlling Interests rose 4.52% year-over-year to $2.1 million; the trailing twelve-month figure through Dec 2023 stood at $4.0 million (up 110.1% YoY), and the FY2023 full-year result was -$2.5 million, changed N/A from the prior year.
- Income from Non-Controlling Interests for Q4 2023 stood at $2.1 million, up from $2.0 million in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $2.1 million in Q4 2023, with the low at -$57538.3 in Q4 2020.
- Average Income from Non-Controlling Interests over 5 years is $792356.0, with a median of -$13193.0 recorded in 2021.
- Year-over-year, Income from Non-Controlling Interests plunged 272.4% in 2020 and soared 15102.01% in 2022.
- Tracing IMRN's Income from Non-Controlling Interests over 5 years: stood at -$15450.8 in 2019, then sank by 272.4% to -$57538.3 in 2020, then jumped by 77.07% to -$13193.0 in 2021, then soared by 15102.01% to $2.0 million in 2022, then advanced by 4.52% to $2.1 million in 2023.
- The last three Income from Non-Controlling Interests figures came in at $2.1 million (Q4 2023), $2.0 million (Q4 2022), and -$13193.0 (Q4 2021), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.75 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 2.07 Mn |
| Dec 31, 2022 | 1.98 Mn |
| Dec 31, 2021 | -13,193.04 |
| Dec 31, 2020 | -57,538.29 |
| Dec 31, 2019 | -15,450.84 |
| Dec 31, 2018 | 1.69 Mn |
| Dec 31, 2017 | -1.45 Mn |
| Dec 31, 2016 | -2.60 Mn |
| Jun 30, 2016 | -3.28 Mn |